Cargando…

(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

PURPOSE: Recent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer’s disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which d...

Descripción completa

Detalles Bibliográficos
Autores principales: Moscoso, Alexis, Silva-Rodríguez, Jesús, Aldrey, Jose Manuel, Cortés, Julia, Pías-Peleteiro, Juan Manuel, Ruibal, Álvaro, Aguiar, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921113/
https://www.ncbi.nlm.nih.gov/pubmed/34581847
http://dx.doi.org/10.1007/s00259-021-05493-y
_version_ 1784669267315130368
author Moscoso, Alexis
Silva-Rodríguez, Jesús
Aldrey, Jose Manuel
Cortés, Julia
Pías-Peleteiro, Juan Manuel
Ruibal, Álvaro
Aguiar, Pablo
author_facet Moscoso, Alexis
Silva-Rodríguez, Jesús
Aldrey, Jose Manuel
Cortés, Julia
Pías-Peleteiro, Juan Manuel
Ruibal, Álvaro
Aguiar, Pablo
author_sort Moscoso, Alexis
collection PubMed
description PURPOSE: Recent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer’s disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which demyelination, as measured with Aβ PET, contributes to AD progression remains unexplored. METHODS: Participants with concurrent (18)F-florbetapir (FBP) PET, MRI, and cerebrospinal fluid (CSF) examinations were included (241 cognitively normal, 347 Aβ-positive cognitively impaired, and 207 Aβ-negative cognitively impaired subjects). A subset of these participants had also available diffusion tensor imaging (DTI) images (n = 195). We investigated cross-sectional associations of FBP retention in the white matter (WM) with MRI-based markers of WM degeneration, AD clinical progression, and fluid biomarkers. In longitudinal analyses, we used linear mixed models to assess whether FBP retention in normal-appearing WM (NAWM) predicted progression of WM hyperintensity (WMH) burden and clinical decline. RESULTS: In AD-continuum individuals, FBP retention in NAWM was (1) higher compared with WMH regions, (2) associated with DTI-based measures of WM integrity, and (3) associated with longitudinal progression of WMH burden. FBP uptake in WM decreased across the AD continuum and with increasingly abnormal CSF biomarkers of AD. Furthermore, FBP retention in the WM was associated with large-calibre axon degeneration as reflected by abnormal plasma neurofilament light chain levels. Low FBP uptake in NAWM predicted clinical decline in preclinical and prodromal AD, independent of demographics, global cortical Aβ, and WMH burden. Most of these associations were also observed in Aβ-negative cognitively impaired individuals. CONCLUSION: These results support the hypothesis that FBP retention in the WM is myelin-related. Demyelination levels progressed across the AD continuum and were associated with clinical progression at early stages, suggesting that this pathologic process might be a relevant degenerative feature in the disease course. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05493-y.
format Online
Article
Text
id pubmed-8921113
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89211132022-03-17 (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum Moscoso, Alexis Silva-Rodríguez, Jesús Aldrey, Jose Manuel Cortés, Julia Pías-Peleteiro, Juan Manuel Ruibal, Álvaro Aguiar, Pablo Eur J Nucl Med Mol Imaging Original Article PURPOSE: Recent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer’s disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which demyelination, as measured with Aβ PET, contributes to AD progression remains unexplored. METHODS: Participants with concurrent (18)F-florbetapir (FBP) PET, MRI, and cerebrospinal fluid (CSF) examinations were included (241 cognitively normal, 347 Aβ-positive cognitively impaired, and 207 Aβ-negative cognitively impaired subjects). A subset of these participants had also available diffusion tensor imaging (DTI) images (n = 195). We investigated cross-sectional associations of FBP retention in the white matter (WM) with MRI-based markers of WM degeneration, AD clinical progression, and fluid biomarkers. In longitudinal analyses, we used linear mixed models to assess whether FBP retention in normal-appearing WM (NAWM) predicted progression of WM hyperintensity (WMH) burden and clinical decline. RESULTS: In AD-continuum individuals, FBP retention in NAWM was (1) higher compared with WMH regions, (2) associated with DTI-based measures of WM integrity, and (3) associated with longitudinal progression of WMH burden. FBP uptake in WM decreased across the AD continuum and with increasingly abnormal CSF biomarkers of AD. Furthermore, FBP retention in the WM was associated with large-calibre axon degeneration as reflected by abnormal plasma neurofilament light chain levels. Low FBP uptake in NAWM predicted clinical decline in preclinical and prodromal AD, independent of demographics, global cortical Aβ, and WMH burden. Most of these associations were also observed in Aβ-negative cognitively impaired individuals. CONCLUSION: These results support the hypothesis that FBP retention in the WM is myelin-related. Demyelination levels progressed across the AD continuum and were associated with clinical progression at early stages, suggesting that this pathologic process might be a relevant degenerative feature in the disease course. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05493-y. Springer Berlin Heidelberg 2021-09-28 2022 /pmc/articles/PMC8921113/ /pubmed/34581847 http://dx.doi.org/10.1007/s00259-021-05493-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Moscoso, Alexis
Silva-Rodríguez, Jesús
Aldrey, Jose Manuel
Cortés, Julia
Pías-Peleteiro, Juan Manuel
Ruibal, Álvaro
Aguiar, Pablo
(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
title (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
title_full (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
title_fullStr (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
title_full_unstemmed (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
title_short (18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
title_sort (18)f-florbetapir pet as a marker of myelin integrity across the alzheimer’s disease spectrum
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921113/
https://www.ncbi.nlm.nih.gov/pubmed/34581847
http://dx.doi.org/10.1007/s00259-021-05493-y
work_keys_str_mv AT moscosoalexis 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT silvarodriguezjesus 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT aldreyjosemanuel 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT cortesjulia 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT piaspeleteirojuanmanuel 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT ruibalalvaro 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT aguiarpablo 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum
AT 18fflorbetapirpetasamarkerofmyelinintegrityacrossthealzheimersdiseasespectrum